vs

Side-by-side financial comparison of Cherry Hill Mortgage Investment Corp (CHMI) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $11.8M, roughly 1.1× Cherry Hill Mortgage Investment Corp). On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -37.2%). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -15.2%).

Cherry Hill Mortgage Investment Corp is a U.S.-headquartered real estate finance firm focused on acquiring, investing in and managing residential mortgage-related assets. Its core holdings include agency mortgage-backed securities, residential loans and mortgage servicing rights, operating primarily in the U.S. domestic housing finance market.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

CHMI vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.1× larger
RNA
$12.5M
$11.8M
CHMI
Growing faster (revenue YoY)
RNA
RNA
+471.2% gap
RNA
434.0%
-37.2%
CHMI
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-15.2%
CHMI

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CHMI
CHMI
RNA
RNA
Revenue
$11.8M
$12.5M
Net Profit
$-174.4M
Gross Margin
78.9%
Operating Margin
72.1%
-1513.5%
Net Margin
-1398.3%
Revenue YoY
-37.2%
434.0%
Net Profit YoY
-117.0%
EPS (diluted)
$0.18
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHMI
CHMI
RNA
RNA
Q4 25
$11.8M
Q3 25
$8.6M
$12.5M
Q2 25
$6.0M
$3.8M
Q1 25
$-3.0M
$1.6M
Q4 24
$18.7M
$3.0M
Q3 24
$-7.1M
$2.3M
Q2 24
$6.6M
$2.0M
Q1 24
$16.3M
$3.5M
Net Profit
CHMI
CHMI
RNA
RNA
Q4 25
Q3 25
$4.5M
$-174.4M
Q2 25
$1.6M
$-157.3M
Q1 25
$-7.0M
$-115.8M
Q4 24
$-102.3M
Q3 24
$-12.4M
$-80.4M
Q2 24
$784.0K
$-70.8M
Q1 24
$12.1M
$-68.9M
Gross Margin
CHMI
CHMI
RNA
RNA
Q4 25
78.9%
Q3 25
73.2%
Q2 25
67.7%
Q1 25
183.4%
Q4 24
83.3%
Q3 24
145.3%
Q2 24
47.5%
Q1 24
83.9%
Operating Margin
CHMI
CHMI
RNA
RNA
Q4 25
72.1%
Q3 25
56.0%
-1513.5%
Q2 25
44.4%
-4448.7%
Q1 25
223.6%
-8360.9%
Q4 24
76.2%
-4069.6%
Q3 24
171.8%
-4200.9%
Q2 24
22.0%
-4040.4%
Q1 24
78.0%
-2178.6%
Net Margin
CHMI
CHMI
RNA
RNA
Q4 25
Q3 25
52.7%
-1398.3%
Q2 25
25.9%
-4089.3%
Q1 25
229.2%
-7360.0%
Q4 24
-3439.5%
Q3 24
175.8%
-3441.7%
Q2 24
11.9%
-3461.8%
Q1 24
73.7%
-1943.4%
EPS (diluted)
CHMI
CHMI
RNA
RNA
Q4 25
$0.18
Q3 25
$0.05
$-1.27
Q2 25
$-0.03
$-1.21
Q1 25
$-0.29
$-0.90
Q4 24
$0.30
$-0.80
Q3 24
$-0.49
$-0.65
Q2 24
$-0.06
$-0.65
Q1 24
$0.32
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHMI
CHMI
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$54.9M
$350.2M
Total DebtLower is stronger
$146.3M
Stockholders' EquityBook value
$236.0M
$1.9B
Total Assets
$1.5B
$2.1B
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHMI
CHMI
RNA
RNA
Q4 25
$54.9M
Q3 25
$55.4M
$350.2M
Q2 25
$58.0M
$243.9M
Q1 25
$47.3M
$254.2M
Q4 24
$46.3M
$219.9M
Q3 24
$50.2M
$370.2M
Q2 24
$52.4M
$575.8M
Q1 24
$47.5M
$471.4M
Total Debt
CHMI
CHMI
RNA
RNA
Q4 25
$146.3M
Q3 25
$148.0M
Q2 25
$150.1M
Q1 25
$150.1M
Q4 24
$152.1M
Q3 24
$151.8M
Q2 24
$160.5M
Q1 24
$167.5M
Stockholders' Equity
CHMI
CHMI
RNA
RNA
Q4 25
$236.0M
Q3 25
$233.1M
$1.9B
Q2 25
$229.9M
$1.2B
Q1 25
$226.6M
$1.3B
Q4 24
$230.3M
$1.4B
Q3 24
$236.7M
$1.5B
Q2 24
$234.5M
$1.2B
Q1 24
$247.0M
$830.9M
Total Assets
CHMI
CHMI
RNA
RNA
Q4 25
$1.5B
Q3 25
$1.5B
$2.1B
Q2 25
$1.5B
$1.4B
Q1 25
$1.4B
$1.5B
Q4 24
$1.5B
$1.6B
Q3 24
$1.6B
$1.6B
Q2 24
$1.4B
$1.3B
Q1 24
$1.4B
$951.5M
Debt / Equity
CHMI
CHMI
RNA
RNA
Q4 25
0.62×
Q3 25
0.63×
Q2 25
0.65×
Q1 25
0.66×
Q4 24
0.66×
Q3 24
0.64×
Q2 24
0.68×
Q1 24
0.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHMI
CHMI
RNA
RNA
Operating Cash FlowLast quarter
$19.1M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHMI
CHMI
RNA
RNA
Q4 25
$19.1M
Q3 25
$-2.4M
$-156.2M
Q2 25
$12.5M
$-199.7M
Q1 25
$682.0K
$-124.8M
Q4 24
$-4.7M
$-99.9M
Q3 24
$4.4M
$-65.6M
Q2 24
$4.1M
$-65.0M
Q1 24
$-19.1M
$-70.4M
Free Cash Flow
CHMI
CHMI
RNA
RNA
Q4 25
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
CHMI
CHMI
RNA
RNA
Q4 25
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
CHMI
CHMI
RNA
RNA
Q4 25
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Cash Conversion
CHMI
CHMI
RNA
RNA
Q4 25
Q3 25
-0.53×
Q2 25
7.98×
Q1 25
Q4 24
Q3 24
Q2 24
5.18×
Q1 24
-1.58×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons